Iron management in chronic kidney disease : Conclusions from a "kidney disease : Improving Global Outcomes" (KDIGO) controversies conference

Show simple item record Obrador Vera, Gregorio Tomás 2017-10-24T22:58:09Z 2017-10-24T22:58:09Z 2016
dc.identifier.citation Macdougall, I. C., Bircher, A. J., Eckardt, K. U., Obrador Vera, G. T,, Pollock, C. A., Stenvinkel, P. ... y Zakharova E. (2016). Iron management in chronic kidney disease: Conclusions from a "kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney International, 89 (1) 28-39. DOI: 10.1016/j.kint.2015.10.002
dc.identifier.issn 2-s2.0-84973130364
dc.identifier.issn 0085-2538
dc.identifier.issn 1564-0604
dc.identifier.other Campus Ciudad de México
dc.description.abstract Before the introduction of erythropoiesis-stimulating agents (ESAs) in 1989, repeated transfusions given to patients with end-stage renal disease caused iron overload, and the need for supplemental iron was rare. However, with the widespread introduction of ESAs, it was recognized that supplemental iron was necessary to optimize hemoglobin response and allow reduction of the ESA dose for economic reasons and recent concerns about ESA safety. Iron supplementation was also found to be more efficacious via intravenous compared to oral administration, and the use of intravenous iron has escalated in recent years. The safety of various iron compounds has been of theoretical concern due to their potential to induce iron overload, oxidative stress, hypersensitivity reactions, and a permissive environment for infectious processes. Therefore, an expert group was convened to assess the benefits and risks of parenteral iron, and to provide strategies for its optimal use while mitigating the risk for acute reactions and other adverse effects. © 2016 International Society of Nephrology.
dc.description.tableofcontents Ciencias de la Salud
dc.publisher Kidney International
dc.publisher Elsevier B.V.
dc.relation Versión aceptada
dc.relation.ispartof REPOSITORIO SCRIPTA
dc.relation.ispartof OPENAIRE
dc.rights Acceso Embargado
dc.source Kidney International
dc.subject Chronic kidney disease
dc.subject Hypersensitivity
dc.subject Infections
dc.subject Iron
dc.subject Overload
dc.subject Oxidative stress
dc.subject Cardiovascular diseases
dc.subject Chemically induced
dc.subject Complication
dc.subject Hypersensitivity
dc.subject Iron overload
dc.subject Metabolism
dc.subject Oxidative stress
dc.subject Renal Insufficiency, Chronic
dc.subject Cardiovascular diseases
dc.subject Ferritins
dc.subject Hematinics
dc.subject Hemoglobins
dc.subject Hepcidins
dc.subject Hypersensitivity
dc.subject Infection
dc.subject Oxidative Stress
dc.subject Renal Insufficiency, Chronic
dc.subject.classification MEDICINA Y CIENCIAS DE LA SALUD
dc.title Iron management in chronic kidney disease : Conclusions from a "kidney disease : Improving Global Outcomes" (KDIGO) controversies conference
dc.type Contribución a congreso
dcterms.audience Investigadores
dcterms.audience Estudiantes
dcterms.audience Maestros

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Acceso Embargado Except where otherwise noted, this item's license is described as Acceso Embargado

Search Scripta

Advanced Search


My Account